A citation-based method for searching scientific literature

Mary E Ropka, Jess Keim, John T Philbrick. J Clin Oncol 2010
Times Cited: 155







List of co-cited articles
563 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
592
46

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
42

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
357
41

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
S G Smith, I Sestak, A Forster, A Partridge, L Side, M S Wolf, R Horne, J Wardle, J Cuzick. Ann Oncol 2016
145
40

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
404
35

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
255
30

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
862
28

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
212
26

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Sharon L Bober, Lizbeth A Hoke, Rosemary B Duda, Meredith M Regan, Nadine M Tung. J Clin Oncol 2004
114
26

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
25

Patient reluctance toward tamoxifen use for breast cancer primary prevention.
E R Port, L L Montgomery, A S Heerdt, P I Borgen. Ann Surg Oncol 2001
158
23

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, Joseph P Costantino, Steve Cummings, Andrea DeCensi, Mitch Dowsett, John F Forbes, Leslie Ford, Andrea Z LaCroix,[...]. Lancet 2013
286
23

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
Andrew N Freedman, Barry I Graubard, Sowmya R Rao, Worta McCaskill-Stevens, Rachel Ballard-Barbash, Mitchell H Gail. J Natl Cancer Inst 2003
182
21

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
18


Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
Angela Fagerlin, Brian J Zikmund-Fisher, Vijayan Nair, Holly A Derry, Jennifer B McClure, Sarah Greene, Azadeh Stark, Sharon Hensley Alford, Paula Lantz, Daniel F Hayes,[...]. Breast Cancer Res Treat 2010
69
24

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Jack Cuzick, John F Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell. J Natl Cancer Inst 2007
367
17


Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.
L S Donnelly, D G Evans, J Wiseman, J Fox, R Greenhalgh, J Affen, I Juraskova, P Stavrinos, S Dawe, J Cuzick,[...]. Br J Cancer 2014
62
27

Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
Angela Fagerlin, Amanda J Dillard, Dylan M Smith, Brian J Zikmund-Fisher, Rosemarie Pitsch, Jennifer B McClure, Sarah Greene, Sharon Hensley Alford, Vijayan Nair, Daniel F Hayes,[...]. Breast Cancer Res Treat 2011
60
26

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
276
16

"Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital.
Talya Salant, Pamela S Ganschow, Olufunmilayo I Olopade, Diane S Lauderdale. J Gen Intern Med 2006
53
30


Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
Erika A Waters, Kathleen A Cronin, Barry I Graubard, Paul K Han, Andrew N Freedman. Cancer Epidemiol Biomarkers Prev 2010
110
15

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Silvana Martino, Jane A Cauley, Elizabeth Barrett-Connor, Trevor J Powles, John Mershon, Damon Disch, Roberta J Secrest, Steven R Cummings. J Natl Cancer Inst 2004
443
15

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Andrew N Freedman, Binbing Yu, Mitchell H Gail, Joseph P Costantino, Barry I Graubard, Victor G Vogel, Garnet L Anderson, Worta McCaskill-Stevens. J Clin Oncol 2011
128
15

Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
516
15

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
152
14

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Erika A Waters, Timothy S McNeel, Worta McCaskill Stevens, Andrew N Freedman. Breast Cancer Res Treat 2012
109
13

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
717
13


Factors affecting breast cancer risk reduction practices among California physicians.
Celia Patricia Kaplan, Jennifer S Haas, Eliseo J Pérez-Stable, Genevieve Des Jarlais, Steven E Gregorich. Prev Med 2005
73
17

Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Laura L Reimers, Parijatham S Sivasubramanian, Dawn Hershman, Mary Beth Terry, Heather Greenlee, Julie Campbell, Kevin Kalinsky, Matthew Maurer, Ramona Jayasena, Rossy Sandoval,[...]. Breast J 2015
25
52

Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.
Meghna S Trivedi, Austin M Coe, Alejandro Vanegas, Rita Kukafka, Katherine D Crew. Cancer Prev Res (Phila) 2017
25
52

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S R Cummings, S Eckert, K A Krueger, D Grady, T J Powles, J A Cauley, L Norton, T Nickelsen, N H Bjarnason, M Morrow,[...]. JAMA 1999
11

Women's views on chemoprevention of breast cancer: qualitative study.
R Heisey, N Pimlott, M Clemons, S Cummings, N Drummond. Can Fam Physician 2006
44
25

Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Joy Melnikow, Debora Paterniti, Rahman Azari, Christina Kuenneth, Stephen Birch, Miriam Kuppermann, James Nuovo, Janet Keyzer, Stuart Henderson. Cancer 2005
61
18

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Elizabeth Barrett-Connor, Lori Mosca, Peter Collins, Mary Jane Geiger, Deborah Grady, Marcel Kornitzer, Michelle A McNabb, Nanette K Wenger. N Engl J Med 2006
687
11

Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Julia Tchou, Nanjiang Hou, Alfred Rademaker, V Craig Jordan, Monica Morrow. Cancer 2004
65
16

Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
Ida J Korfage, Andrea Fuhrel-Forbis, Peter A Ubel, Brian J Zikmund-Fisher, Sarah M Greene, Jennifer B McClure, Dylan M Smith, Sharon Hensley Alford, Angela Fagerlin. Breast Cancer Res 2013
28
39

The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.
Suzanne B Coopey, Emanuele Mazzola, Julliette M Buckley, John Sharko, Ahmet K Belli, Elizabeth M H Kim, Fernanda Polubriaginof, Giovanni Parmigiani, Judy E Garber, Barbara L Smith,[...]. Breast Cancer Res Treat 2012
78
14

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Kala Visvanathan, Rowan T Chlebowski, Patricia Hurley, Nananda F Col, Mary Ropka, Deborah Collyar, Monica Morrow, Carolyn Runowicz, Kathleen I Pritchard, Karen Hagerty,[...]. J Clin Oncol 2009
202
10

Implementation in a large health system of a program to identify women at high risk for breast cancer.
William L Owens, Thomas J Gallagher, Michael J Kincheloe, Victoria L Ruetten. J Oncol Pract 2011
30
33


Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.
Richard G Roetzheim, Ji-Hyun Lee, William Fulp, Elizabeth Matos Gomez, Elissa Clayton, Sharon Tollin, Nazanin Khakpour, Christine Laronga, Marie Catherine Lee, John V Kiluk. Breast 2015
31
32

Barriers to the Use of Breast Cancer Risk Reduction Therapies.
Arvind Bambhroliya, Mariana Chavez-MacGregor, Abenaa M Brewster. J Natl Compr Canc Netw 2015
17
58

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
Andrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Silvia Caviglia, Franca Avino, Laura Cortesi, Cristiana Taverniti, Maria Grazia Pacquola, Fabio Falcini, Marcella Gulisano,[...]. J Clin Oncol 2019
83
12

Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers.
Susan A Sabatino, Ellen P McCarthy, Russell S Phillips, Risa B Burns. Cancer Detect Prev 2007
80
11

Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
Gabriella Rondanina, Matteo Puntoni, Gianluca Severi, Clara Varricchio, Anna Zunino, Irene Feroce, Bernardo Bonanni, Andrea Decensi. J Clin Oncol 2008
30
30

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
J Cuzick, J Forbes, R Edwards, M Baum, S Cawthorn, A Coates, A Hamed, A Howell, T Powles. Lancet 2002
526
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.